In the last decade much progress has been made in the study of blood coagula tion and hemosta.sis. In company with the progress of anticoagulant therapy, the mechanism of blood coagulation has been greatly elucidated, and the factors of blood coagulation were defined by the International Committee on Blood Coagula tion in 1962. Apart from some controversies on the theoretical model and definition, the factors are generally accepted.
Certain factors of blood coagulation were made clear by the studies of the cases of hemorrhagic diathesis. Patek (1937) had first recognized in the classical hemophilia a defect in the plasma globulin which is now called antihemophilic globulin (AHG). Then, the deficiencies of plasma thromboplastin component (PTC) and plasma thromboplastin antecedent (PTA) were discovered by Aggeler (1952) and Rosenthal (1953) .
Furthermore, not only the congenital or familial coagulation defects such as Hageman traits and Stuart factor deficiency, but also the acquired coagulation defects in liver damage, leukemia, aplastic anemia and others have been confirmed.1 Thus, the pathophysi.ology of hemorrhage in hemophiliacs or hemophiloids and in acquired hemorrhagic diathesis has been clarified to a great extent along with the progress in the analysis of physiochemistry of the blood coagulation. Therefore, reasonable treatments have been clinically attempted with new hemostatics such as vitamin K, adrenochromes, steroid hormones, tissue extracts and trans-4 aminomethyl cyclohexane-carboxylic acid. . RESULTS
A) Cases with normal PCT
Fifteen to 48 ml of serum were transfused in 17 cases with normal PCT. The results are shown in Tables 1 and 2 . There was no difference in response according to different procedures in serum preparation, nor was there any clear relation between the amount of transfused serum and the effectiveness or side-effects.
In 2 of 5 cases with bleeding evidence a marked clinical effect was obtained by the serum transfusion. In Case 1 of a 47-year-old male with gastric ulcer the It is of interest that most of the patients had originally a rather short clotting time.
As for PT and TT, there was no difference in effectiveness between hemorrhagic and non-hemorrhagic cases as shown in Table 2 . The changes in both tests in the accelerated cases are shown in Fig. 6 .
The clotting time shortened gradually, and the maximum shortening was attained in 2 hours, but some effectiveness was observed over 6 hours.
In the comparative study of the effect of serum transfusion and that of fresh plasma, there was a clear difference, as shown in Fig. 7 . It was obvious that, unlike the serum transfusion, the plasma transfusion did not cause any change in the clotting time in cases of normal PCT.
B) Cases with abnormal PCT 1) Hemophilia A. Two cases of hemophilia A, which was proved by TGT, were subjected to the study. Case 1. H.A., 21-year-old male:This patient had had bleeding tendency since childhood, such as hematuria, tarry stool, subcutaneous hematoma and epistaxis. He was admitted to our department because of uncontrollable bleeding after extraction of the left inferior first great molar tooth. 25 ml of serum, antihemophilic plasma (Hyland lab.) and fresh plasma were transfused at 48-hour intervals. Figs. 8-10 give the result of each infusion, which indicates that fresh serum can correct the clotting time of hemophilia A as effectively as fresh plasma. The duration of effectiveness of serum was 6 hours, which was the same as that of fresh plasma. Serum was superior to antihemophilic plasma, the effect of which lasted for less than 6 hours.
Case 2. H.O., 30-year-old male:This patient also had a bleeding tendency with family history since 19 years of age. He was hospitalized because of sub cutaneous hematoma in the gluteal region. He was transfused 25 ml of serum and 48 hours later the same amount of fresh plasma. As shown in Fig. 11 , the plasma g/100ml and hypoproteinemia 4.4g/100 ml. There was no evidence of hepatic lesion, but the coagulation time was prolonged. Transfusion of 18 ml of fresh serum resulted in shortening of PCT from abnormal range to normal, and it was still in the normal range after 6 hours. A slight shortening of PT and TT was observed (Fig. 14) . 5) Hepatitis chronica. Case 16 of a 36-year-old male (Table 1 ) exhibited a slight prolongation in clotting time (PT 18.0 see, TT 61 sec and PCT 134 see). This patient was admitted to the hospital because of long-lasting severe icterus with total serum bilirubin of 12mg/100 ml on admission, which after the treatment of 1-year duration decreased to 2.5mg/100 ml (direct 2.0 mg/100 ml;indirect 0.5 mg/100ml). Other laboratory data were as follows:Z.S.T. 17.1 K.U., T.T.T. 3.9 M.U., T.P. 6.4 g/100ml, A/G 0.6, GOT 11.0 K.U., and GPT 20.0 K.U. There were no esophageal varices, but slightly hard liver edge was palpable. The trans fusion of 20 ml of serum shortened PT to 17.6 see, TT to 47 see, and PCT to 101 sec. 6) Leukemia. Serum transfusion was done in 8 cases of leukemia:a case of chronic myelocytic leukemia, 2 of monocytic leukemia and 5 of acute myelocytic leukemia, including one of promyelocytic leukemia. In Table 3 the amount of transfused serum and the result are suimnarized. In all the cases PCT was abnormal before serum transfusion. As shown in Fig. 15 , shortening of PCT within 15 minutes after transfusion was seen in 6 cases, and prolongation in 2 cases, in which the clotting time, however, returned to normal after one hour and was still shortened by 20% of the original after 12 hours.
The mean value of shortening of the clotting time was about 15% of the original value. The clotting time was shortened in 15 minutes to 3 hours after transfusion, and then gradually prolonged even to 25% in 6 to 24 hours. PT and TT showed a temporary prolongation in 2 and 3 cases respectively. In both tests, however, the mean value showed no significant change (Fig. 16) . 
D) (Side-effects
Palpitation, flushing of the face and headache were complained of by some patients 3 to 5 minutes after transfusion, which subsided spontaneously within 5 to 10 minutes. These side-effects were seen in 5 of 17 cases with normal PCT and 
DISCUSSION
The shortening of PCT following serum transfusion occurred in 13 of 17 cases with normal PCT. This result suggests that serum transfusion is certainly a useful hemostatic procedure in hemorrhagic disorders with coagulation defects. In 2 of 5 cases with normal PCT and in 7 of 9 cases with abnormal PCT hemorrhagic symptoms were definitely improved by serum transfusion.
As shown in the in vitro experiment by Yoshida,4 shortening of the clotting time was seen not only in PCT but also in PT and TT even in cases with normal PCT.
This finding agrees with his assumption that serum promotes blood coagulation probably by its enzymatic factor(s), acting on more than one phase of the coagulation steps.
In 4 cases rather short original clotting times were unchanged or prolonged after serum transfusion. It may be assumed that serum induces a vital reaction in the system of blood coagulation and actuates the homeostatic mechanism properly in vivo. Shortening of the clotting time occurred most strongly immediately after the transfusion in most of the cases with normal coagulability and in heino philia A, but in leukemia and in some cases with normal coagulability the shorten ing gradually progressed with time, the maximum appearing after 6 to 8 hours. If the serum shortened the clotting time only by correcting the deficiency in the coagulation system, the response would have appeared at the maximum immedi ately after serumm transfusion. Therefore, it may be speculated that serum transfusion would induce a continuous reaction in vivo. However, the question still remains whether the shortening of clotting time was brought about by formation of intravascular clotting, thereby producing serum factor(s), or by other unknown mechanism.
The maximum shortening of PT and TT was attained approximately 2 hours after serum transfusion. However, it is difficult to find a plausible explanation as to why the maximum effect appears at different times in these tests and PCT. In contrast with serum, plasma transfusion in patients with normal coagulability does not induce a change in the clotting time. This can be well interpreted by the fact that normal cases have originally ample coagulation factors. The question why serum, not plasma, can induce shortening of the clotting time may be compre hended by Yoshida's hypothesis4 that the transfused serum shortens the clotting time enzymatically by enhancing the `chain' reaction of coagulation steps. In hemophilia A the hypothesis was clinically supported by the fact that serum, supposedly lacking AHG, was just as effective as normal plasma and antihemophilia plasma in shortening the clotting time of AHG deficient plasma.
In the report of serum transfusion in von Willebrand's disease by Fantl and Sawers,21 it was described that factor VIII in 10% in original increased to above 80% 4 to 8 hours after serum transfusion. In hemophilia B and C, therefore, it may be expected that serum transfusion would correct prolonged clotting time both by supplying the lacking factor and by installing the clot promoting factor(s). The controversial report by Nour-Eldin and Wilkinson8 was concerned with only the results of TGT, which does not represent the coagulability of blood as a whole. It is interesting, however, that they also affirmed the favorable effect of serum on the clotting time.
Serum transfusion in aplastic anemia exerted a marked favorable effect not only by correcting the clotting time but also by shortening the bleeding time. This result certainly suggests that serum may contain some unknown components con cerning capillary fragility or platelet function other than shortening of clotting time. As in aplastic anemia, the hemorrhagic diathesis may represent mainly increased capillary fragility and hypofunetion of platelets.1 It is not known whether or not the serum reacts with platelets and/or vessels, but the following reports may give a clue to this problem. Jackson et al.27 and James et al .28 described that many factors such as thrombin, factors VIII and IX and fibrinogen were involved in platelet aggregation, progress of metamorphosis, clot formation and retraction. This suggests that substances concomitantly produced abundantly in the course of coagulation may promote the reaction of platelets. The transfused serum may also react directly against heparin in the vessel wall as reported by Mustard et al. 29 The author did not study the changes in the platelet counts. However, Wessler and Morris3 reported in his animal experiments of thrombus formation that serum infusion resulted in marked thrombocytopenia and impair ment of thromboplastin generation in accordance with decreased whole blood clotting time. At any rate, treatment of hemorrhagic diathesis in aplastic anemia is still difficult today, and serum transfusion would be one of the recommendable procedures.
As for anticoagulant therapy it was reported that hemorrhage was recognized as a major complication in 5% of the patients treated on a short tune basis.30 Sometimes surgical operation may be needed in patients under anticoagulant treat ment. On such occasion, acute correction of prolonged coagulation time is possible by serum transfusion.
As mentioned by Alexander,30 plasma or plasma fraction rich in pertinent clotting factors should be immediately infused together with vitamin K, because the effect of vitamin K might be attained within 24 hours. Although ordinary ACD bank plasma is fully potent in the factors in spite of anticoagulants, patients with impaired cardiac activity may not tolerate the infusion of three units of stored blood, which is required to normalize the clotting time. As the coumarin congeners act in depressing the factors II, VII, IX, all of which are in activated form in serum,30 serum rather than plasma is expected to be more effective with a less amount of transfusion. In one of the author's cases, an infusion of 20 ml serum to a patient under Warfarin therapy showed a definite shortening of the clotting time.
In cases with acquired coagulation defect seen in liver damage, choledochus stasis or malabsorption syndrome, the deficient factors are usually those of the serum. So, serum transfusion may be well effective. In a case of stomach cancer with prolonged coagulation time, serum transfusion resulted in a marked correction as expected. Serum transfusion of 20 ml was quite effective also in Case 16 in Table 1 , whose liver function was severely impaired. Therefore, in hemorrhagic diathesis with hepatocellular damage, the treatment of choice is the serum transfusion.
The fact that serum transfusion showed a marked clinical hemostatic effect in 5 of 8 cases of leukemia brings about a new aspect in the treatment of trouble some hemorrhagic diathesis in the disease. As the causes of hemorrhagic diathesis in leukemia the followings are generally referred to ;1) thrombocytopenia or non-functioning thrombocytes, 2) increased capillary fragility, 3) lack of coagulation factors, 4) increase of circulating anticoagulants and 5) elevated plasmin activity. The most important cause is said to be a lack of or defect in thrombocytes and increased capillary fragility. Therefore, the mechanism of effectiveness of serum transfusion may be explained as an acceleration in blood coagulation in the first place, but the decrease of purpura, reduction of capillary fragility, shortening of bleeding time, etc., suggest that the infused serum produces or stimulates a component which may be concerned with platelet function, vessel wall, and SUMMARY 1) Serum transfusion from 15 to 55ml was done in 30 cases, and PT, TT and PCT were examined at various interals. A marked shortening of clotting time was seen in 13 of 17 cases with normal coagulability and 11 of 13 cases with abnormal one.
2) In 17 cases with hemorrhagic diathesis a marked clinical effectiveness was seen in 10 cases as follows : a) Hemorrhage was lessened in bleeding gastric ulcer and essential hematuria in which the PCT was originally within normal range.
b) In 5 of 8 cases of leukemia such favorable effects were seen as decrease of purpura, cease of oozing from the tongue, reduction of capillary fragility, shorten ing of bleeding tinge and improvement in general malaise. The same effects were seen in a case of severe aplastic anemia. c) In cases with liver damage and stomach cancer, the prolonged PCT was shortened.
In aa case under Warfarin treatment, a temporary shortening of clotting time was induced. In two cases of hemophilia A a marked shortening of PCT was induced by serum transfusion of 25 ml.
3) The question why the maximum shortening of the clotting time was not attained immediately after transfusion in some cases and the effect on plasmin activity were discussed.
4) It is concluded that serum transfusion is a useful hemostatic procedure in various hemorrhagic conditions.
